Latest Content


Lindsay Bealor Greenleaf
0:56
Drug Policy Shift: MFN's Impact on Providers
9 hours ago
by
Mike Hollan(+1 more)
Yerem Yeghiazarians
0:50
The Weird Connection Between Cancer and Heart Attacks
3 days ago
Stock.adobe.com
1:01
Market Watch Rx: Merck Joins Top Gainers
6 days ago
by
Nicholas Jacobus
Why China’s R&D Model is Thriving
0:50
Why China’s R&D Model is Thriving
9 days ago
by
Michael Christel(+2 more)
Stock.adobe.com
0:34
Takeaways from Day One at Access USA 2026
10 days ago
by
Nicholas Jacobus(+1 more)
Stock.adobe.com
1:01
Market Watch Rx: Intellia Therapeutics Leads Gainers
13 days ago
by
Nicholas Jacobus
Stock.adobe.com
1:08
What You Need to Know: MFN, Healthcare Spending, and Compounded Medications
13 days ago
by
Mike Hollan
Stock.adobe.com
0:42
What Can Help Patient Support Operations?
14 days ago
by
Nicholas Jacobus(+1 more)
2026 Drug Pipeline Report
1:41
2026 Drug Pipeline Report
14 days ago
by
Michael Christel
Stock.adobe.com
0:51
Measuring Good Patient Access from Bad Patient Access
16 days ago
by
Nicholas Jacobus(+1 more)

Andrew Hall: The Discipline of Conviction

Inside Consano Bio’s bet on first-in-class nerve repair—and what it takes to lead an early-stage biotech through uncertainty.

Andrew Hall: The Discipline of Conviction

Cautious Momentum: Biopharma Review and Outlook

Fresh off 2025, where the sectors delivered strong stock gains and selective financing momentum despite volatile markets, companies navigate policy headwinds, patent cliffs, and shifting global innovation dynamics.

Cautious Momentum: Biopharma Review and Outlook

Pharmaceutical Executive: March 2026 Issue (PDF)

Click the title above for a link to open the Pharmaceutical Executive March 2026 issue in an interactive PDF format.

Pharmaceutical Executive: March 2026 Issue (PDF)

Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles

Industry experts across the biotech sector discuss the latest trends impacting emerging biotech companies, including the challenges of early-stage biotech start-ups, AI integration across the sector, and the most recent innovations.

Navigating Complexity in Emerging Biotech: Innovations, Integrations, and Initial Hurdles

Agentic AI and the Future of Commercial Excellence in Life Sciences

How organizations can gain an edge in the enterprise transformation to unified analytics that's accelerating across pharma.

Agentic AI and the Future of Commercial Excellence in Life Sciences

Podcasts



All News

Pharmaceutical Executive Daily

In today's Pharmaceutical Executive Daily, the Trump administration delays its appeal of the federal ruling blocking RFK Jr.'s vaccine policy overhaul as political pressures mount ahead of the midterm elections, Biogen agrees to acquire Apellis Pharmaceuticals in a deal valued at approximately $5.6 billion, and Pharmaceutical Executive examines the risk-reward calculus facing R&D leaders in today's volatile development environment.

Pharmaceutical Executive podcast

In today's Pharmaceutical Executive Daily, Novo Nordisk launches the first multi-month subscription program for Wegovy targeting cash-paying patients through telehealth partners, Merck enters an $838 million research collaboration with antibody discovery startup Infinimmune, and Eli Lilly agrees to acquire Centessa Pharmaceuticals in a deal valued at up to $7.8 billion to expand into sleep-wake disorder treatments.